Phase 4Completed
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
A Pilot Trial of the Tolerability and Clinical Effectiveness of Letermovir When Used for Secondary Prophylaxis to Prevent Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients
- Sponsor
- Tufts Medical Center (Academic or other)
- Enrollment
- 21 enrolled
- Conditions
- Cytomegalovirus Infections; Infection in Solid Organ Transplant Recipients; Neutropenia; Antiviral Toxicity
- Interventions
- Letermovir
- Ages
- adults, older adults
- Registry
- NCT05626530
Full record on ClinicalTrials.gov
From the registry
This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient. This study is an open label trial in which Letermovir will be prescribed to prevent the recurrence of CMV infection and disease in a solid organ transplant recipient following treatment of CMV infection or disease.
Primary outcomes
- Rate of Relapse after prophylaxis
History
Last registry update
Primary completion
Started
Registered